AstraZeneca PLC (AZNCF)
| Market Cap | 209.59B |
| Revenue (ttm) | 54.98B |
| Net Income (ttm) | 7.77B |
| Shares Out | n/a |
| EPS (ttm) | 4.97 |
| PE Ratio | 26.97 |
| Forward PE | 14.52 |
| Dividend | 3.10 (2.29%) |
| Ex-Dividend Date | Feb 20, 2025 |
| Volume | 8 |
| Average Volume | 1,995 |
| Open | 127.45 |
| Previous Close | 135.36 |
| Day's Range | 127.45 - 135.36 |
| 52-Week Range | 120.64 - 175.00 |
| Beta | 0.18 |
| RSI | 45.47 |
| Earnings Date | Apr 29, 2025 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]
Financial Performance
In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.
Financial StatementsNews
P/E Ratio Insights for AstraZeneca
In the current session, AstraZeneca Inc. (NASDAQ: AZN) is trading at $66.27, after a 2.14% drop. Over the past month, the stock decreased by 1.16% , and in the past year, by 13.98% . With performance...
BioInvent Announces Updated Phase 2a Triple Combination Arm Data of BI-1206, rituximab, and Calquence for the Treatment of Non-Hodgkin's Lymphoma
Latest preliminary data show continued promising clinical activity in NHL patients, with two complete responses (CR), three partial responses (PR), and three stable disease (SD) as best clinical respo...
AstraZeneca to showcase latest research on comprehensive portfolio and pipeline aimed at transforming respiratory diseases at ATS 2025
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca will present the latest clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoraci...
AstraZeneca and GSK in the firing line as Trump targets big pharma: ALEX BRUMMER
No one expected US peace in our time at the Geneva talks with China at the weekend, but what emerged is better than predicted.
Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices
Scott Gottlieb, former FDA commissioner, joins CNBC's 'Squawk on the Street' to discuss how the White House may plan to cut drug prices.
Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices
Novo Nordisk, which generates around 60% of its sales in the U.S., is among the biggest losers in early European trade.
Pharmaceutical stocks slide as Trump vows to cut US prescription drug prices ‘by 30-80%'
President plans to use executive powers, saying US should pay ‘same price as nation that pays the lowest price'
AstraZeneca (AZN) Faces Market Uncertainty Amid Drug Pricing Changes | AZN Stock News
AstraZeneca (AZN) Faces Market Uncertainty Amid Drug Pricing Changes | AZN Stock News
AstraZeneca's bladder cancer treatment shows positive results in trial
IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the POTOMAC Phase III trial showed one year of treatment with AstraZeneca's IMFINZI® (durvalumab) plus standard-of-care BCG inductio...
AstraZeneca, Daiichi post late-stage trial win for Enhertu in early-stage breast cancer
ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11
AstraZeneca and Daiichi Sankyo's ENHERTU followed by THP showed an improved safety profile vs. standard of care First Phase III trial to demonstrate benefit of ENHERTU in early breast cancer Positive ...
Tempus AI Strikes $200M Deal With AstraZeneca, Pathos To Build World's Largest Oncology Model
Tempus AI Inc. (NASDAQ: TEM) during the first quarter secured a multi-million dollar deal to build “the world’s largest foundation model for oncology.” What Happened: During its first-quarter earning...
ENHERTU® Followed by THP Before Surgery Showed Statistically Significant and Clinically Meaningful Improvement in Pathologic Complete Response in Patients With High-Risk HER2 Positive Early-Stage Breast Cancer in DESTINY-Breast11 Phase 3 Trial
Daiichi Sankyo and AstraZeneca's ENHERTU followed by THP showed an improved safety profile versus standard of care First phase 3 trial to demonstrate benefit of ENHERTU in early breast cancer Results ...
Tempus AI raises revenue guidance to $1.25B for 2025, supported by new $200M AstraZeneca deal
AstraZeneca's Triple-Combination Therapy Breztri Hits Primary Goals In Two Pivotal Studies For Asthma
AstraZeneca's Breztri met primary goals in ... Full story available on Benzinga.com
AstraZeneca succeeds in late-stage trials for asthma therapy
Alembic Pharma gets USFDA final nod for Ticagrelor 90 mg, tentative approval for 60 mg
Alembic Pharmaceuticals Limited announced on May 2, 2025, that it has received final approval from the US Food and Drug Administration (USFDA) for its Ticagrelor Tablets, 90 mg, and tentative approval...
AstraZeneca's Breztri meets main goals of late-stage asthma trials
Anglo-Swedish drugmaker AstraZeneca on Friday said its inhaler therapy Breztri Aerosphere met all the main goals of two late-stage trials in patients with uncontrolled asthma.
Step up now or lose jobs to US, AstraZeneca boss Pascal Soriot warns European pharma firms
Pascal Soriot (pictured) said innovation in pharma 'has mostly been funded by the US' as he doubled down on plans to grow the business in America.
What Does the Market Think About AstraZeneca?
AstraZeneca's (NYSE: AZN) short percent of float has fallen 41.18% since its last report. The company recently reported that it has 6.33 million shares sold short , which is 0.2% of all regular share...
AstraZeneca has built resilient supply chains in U.S., China: CEO
AstraZeneca CEO Pascal Soriot discusses earnings, the potential trade tariff impact on the business and the outlook for the firm's key markets.
Pharma firms maastraz
Jimmy Muchechetere, senior equity analyst at Investec, weighs in on the prospect of pharmaceutical tariffs and recent U.S. investment commitments from the sector.
AstraZeneca PLC (AZN) Q1 2025 Earnings Conference Call Transcript
AstraZeneca PLC (NASDAQ:AZN) Q1 2025 Earnings Conference Call April 29, 2025 6:45 AM ETCompany ParticipantsAndy Barnett - Head of IRPascal Soriot -...
AstraZeneca CEO talks tariffs, first quarter earnings
AstraZeneca (AZN) reported mixed first quarter earnings results, missing on revenue estimates but beating on earnings per share (EPS). The company also reaffirmed its 2025 outlook and has highlighted ...